RT Journal Article
SR Electronic
T1 Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.05.21252520
DO 10.1101/2021.03.05.21252520
A1 Chen, Chaoran
A1 Nadeau, Sarah
A1 Topolsky, Ivan
A1 Manceau, Marc
A1 Huisman, Jana S.
A1 Jablonski, Kim Philipp
A1 Fuhrmann, Lara
A1 Dreifuss, David
A1 Jahn, Katharina
A1 Beckmann, Christiane
A1 Redondo, Maurice
A1 Kobel, Olivier
A1 Noppen, Christoph
A1 Risch, Lorenz
A1 Risch, Martin
A1 Wohlwend, Nadia
A1 Kas, Sinem
A1 Bodmer, Thomas
A1 Roloff, Tim
A1 Stange, Madlen
A1 Egli, Adrian
A1 Eckerle, Isabella
A1 Kaiser, Laurent
A1 Denes, Rebecca
A1 Feldkamp, Mirjam
A1 Nissen, Ina
A1 Santacroce, Natascha
A1 Burcklen, Elodie
A1 Aquino, Catharine
A1 de Gouvea, Andreia Cabral
A1 Moccia, Maria Domenica
A1 Grüter, Simon
A1 Sykes, Timothy
A1 Opitz, Lennart
A1 White, Griffin
A1 Neff, Laura
A1 Popovic, Doris
A1 Patrignani, Andrea
A1 Tracy, Jay
A1 Schlapbach, Ralph
A1 Dermitzakis, Emmanouil T.
A1 Harshman, Keith
A1 Xenarios, Ioannis
A1 Pegeot, Henri
A1 Cerutti, Lorenzo
A1 Penet, Deborah
A1 Blin, Anthony
A1 Elies, Melyssa
A1 Althaus, Christian
A1 Beisel, Christian
A1 Beerenwinkel, Niko
A1 Ackermann, Martin
A1 Stadler, Tanja
YR 2021
UL http://medrxiv.org/content/early/2021/04/01/2021.03.05.21252520.abstract
AB Background In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now coined B.1.1.7. Based on the UK data and later additional data from other countries, a transmission advantage of around 40-80% was estimated for this variant [1, 2, 3].Aim The goal of this study is to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time for data from Switzerland.Methods We collected genomic surveillance data from 11.8% of all SARS-CoV-2 confirmed cases across Switzerland between 14.12.2020 and 11.03.2021. It allows us to determine the relative proportion of the B.1.1.7 variant on a daily basis and to quantify the transmission advantage of the B.1.1.7 variant on a national and a regional scale.Results We propose a transmission advantage of 43-52% of B.1.1.7 compared to the other circulating variants. Further, we estimate a reproductive number for B.1.1.7 above 1 for Jan. 1, 2021 until now while the reproductive number for the other variants was below 1. In particular, for the time period up to Jan. 17 we obtain a reproductive number of 1.24 [1.07-1.41] and from Jan. 18 until March 1 we obtain 1.18 [1.06-1.30] based on the whole genome sequencing data. For March 10-16, we obtain 1.14 [1.00-1.26] based on all confirmed cases among which B.1.1.7 is dominant at this stage. Switzerland tightened measures on 18.01.2021 and released measures on 01.03.2021.Conclusion In summary, the dynamics of increase in the frequency of B.1.1.7 is as expected based on the observations in the UK. B.1.1.7 increased in absolute numbers exponentially with the point estimate for the doubling time being around 2-3.5 weeks. Our plots are available online and are currently regularly updated with new data to closely monitor the spread of B.1.1.7.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTS acknowledges funding from the Swiss National Science foundation (Special Call on Coronaviruses; 31CA30_196267 and 31CA30_196348). CA received funding from the European Union Horizon 2020 research and innovation programme - project EpiPose (No 101003688).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics commission (Ethikkommission Nordwest- und Zentralschweiz) confirmed that our study is exempt from ethical oversight as it only considers viral RNA but no human data. The final letter is attached.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll used data and code are publicly available. https://github.com/cevo-public/Quantification-of-the-spread-of-a-SARS-CoV-2-variant